G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 13.24 USD 4.25% Market Closed
Market Cap: 821.3m USD

Relative Value

There is not enough data to reliably calculate the relative value of GHRS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GHRS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-17.5
Median 5Y
-20.1
Industry
21.4
Forward
-15.7
vs History
vs Industry
Median 3Y
-17.3
Median 5Y
-19.3
Industry
16.4
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-19.2
Industry
22.8
vs History
36
vs Industry
16
Median 3Y
2.5
Median 5Y
2.6
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.5
Industry
13
Forward
-9
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-10.4
Industry
16.5
Forward
-8.4
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-12.5
Industry
15.6
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-12.4
Industry
18.7
vs History
26
vs Industry
5
Median 3Y
6.8
Median 5Y
7.5
Industry
1.9

Multiples Across Competitors

GHRS Competitors Multiples
GH Research PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
GH Research PLC
NASDAQ:GHRS
821.3m USD 0 -19.1 -9.4 -9.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
259.1B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP 4.8 30 108.3 158.5
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
CH
Novartis AG
SIX:NOVN
207.2B CHF 4.7 18.2 11.5 14.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.8 14.5 10.1 11.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
IE
G
GH Research PLC
NASDAQ:GHRS
Average P/E: 24.2
Negative Multiple: -19.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
37%
0.8
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
3%
4.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
G
GH Research PLC
NASDAQ:GHRS
Average EV/EBITDA: 439.7
Negative Multiple: -9.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
1%
10.1
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
G
GH Research PLC
NASDAQ:GHRS
Average EV/EBIT: 1 883.3
Negative Multiple: -9.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5